EGFR genotyping of matched urine, plasma and tumor
tissue from NSCLC pts treated with rociletinib
Wakelee et al ASCO 16
•
181 samples had matched pre-treatment results in plasma,
tissue and urine
–
174 were T790M+ by at least 1 sample type (96%)
–
104 were positive by all 3 sample types (57%)
•
Confirmed RR and PFS similar for T790M+ pts identified by tissue,
plasma, and urine test
Sample type
n
Objective RR, PFS
Tissue
443 33.9%, 5.0 mo
Plasma
374 32.1%, 4.1 mo
Urine
169 36.7%, 4.3 mo
